KROS Keros Therapeutics, Inc.

8-K Current Report

Filed: March 4, 2026

Health Care

Pharmaceutical Preparations

Keros Therapeutics, Inc. (KROS) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1)
• Includes "recent business highlights" — likely pipeline or clinical updates material to this clinical-stage biotech

+1 more insights

Other Keros Therapeutics, Inc. 8-K Filings

8-K Mar 9, 2026

8-K Mar 4, 2026

8-K Feb 26, 2026

Get deeper insights on Keros Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.